{"date":"2026-01-31","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4743-2026-01-31-1701-1y9ixlz","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2026-01-31","time":"17:01:59","subject":"公告本公司今日接獲註冊代理人通知，哥倫比亞食品藥物管理局(INVIMA)受理Bonvadis外用乳膏完全傷口適應症醫材產品註冊申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合一（4743），2026-01-31 17:01，「公告本公司今日接獲註冊代理人通知，哥倫比亞食品藥物管理局(INVIMA)受理Bonvadis外用乳膏完全傷口適應症醫材產」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2026-01-31-1554-8syc59","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-01-31","time":"15:54:44","subject":"公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，向美國FDA遞交臨床一期試驗的IND申請。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-01-31 15:54，「公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，向美國FDA遞交臨床一期試驗的IND申請。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}